{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:57:31Z","timestamp":1773381451844,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004192","name":"National Science and Technology Development Agency","doi-asserted-by":"publisher","award":["P-20-52262"],"award-info":[{"award-number":["P-20-52262"]}],"id":[{"id":"10.13039\/501100004192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013238","name":"Faculty of Medicine Siriraj Hospital, Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>COVID-19 pandemic has claimed millions of lives and devastated the health service system, livelihood, and economy in many countries worldwide. Despite the vaccination programs in many countries, the spread of the pandemic continues, and effective treatment is still urgently needed. Although some antiviral drugs have been shown to be effective, they are not widely available. Repurposing of anti-parasitic drugs with in vitro anti-SARS-CoV-2 activity is a promising approach being tested in many clinical trials. Combination of these drugs is a plausible way to enhance their effectiveness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The in vitro anti-SARS-CoV-2 activity of combinations of niclosamide, ivermectin and chloroquine were evaluated in Vero E6 and lung epithelial cells, Calu-3.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All the two-drug combinations showed higher potency resulting in up to 4-fold reduction in the half maximal inhibitory concentration (IC<jats:sub>50<\/jats:sub>) values compared to individual drugs. Among these combinations, niclosamide-ivermectin achieved the highest inhibitory level of over 99%. Combination synergy analysis showed niclosamide-ivermectin combination to have the best synergy score with a mean Loewe synergy score of 4.28 and a peak synergy score of 24.6 in Vero E6 cells and a mean Loewe synergy score of 3.82 and a peak synergy score of 10.86 in Calu-3 cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present study demonstrated the benefit of drug combinations on anti-SARS-CoV-2 activity. Niclosamide and ivermectin showed the best synergistic profile and should be further tested in clinical trials.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-022-00580-8","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T09:02:54Z","timestamp":1655542974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations"],"prefix":"10.1186","volume":"23","author":[{"given":"Kunlakanya","family":"Jitobaom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chompunuch","family":"Boonarkart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suwimon","family":"Manopwisedjaroen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuntaya","family":"Punyadee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suparerk","family":"Borwornpinyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arunee","family":"Thitithanyanont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panisadee","family":"Avirutnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-4291","authenticated-orcid":false,"given":"Prasert","family":"Auewarakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,18]]},"reference":[{"key":"580_CR1","doi-asserted-by":"publisher","first-page":"n1188","DOI":"10.1136\/bmj.n1188","volume":"373","author":"O Dyer","year":"2021","unstructured":"Dyer O. Covid-19: study claims real global deaths are twice official figures. BMJ. 2021;373:n1188.","journal-title":"BMJ"},{"key":"580_CR2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","volume":"5","author":"E Mathieu","year":"2021","unstructured":"Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5:947\u201353.","journal-title":"Nat Hum Behav"},{"key":"580_CR3","unstructured":"FDA Approves First Treatment for COVID-19. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19. Accessed 15 Dec 2021."},{"key":"580_CR4","unstructured":"Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19. Accessed 1 Dec 2021."},{"key":"580_CR5","doi-asserted-by":"publisher","first-page":"173634","DOI":"10.1016\/j.ejphar.2020.173634","volume":"889","author":"Y Wang","year":"2020","unstructured":"Wang Y, Chen L. Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment. Eur J Pharmacol. 2020;889:173634.","journal-title":"Eur J Pharmacol"},{"key":"580_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/cpt.1909","volume":"108","author":"U Arshad","year":"2020","unstructured":"Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, et al. Prioritization of anti-SARS-CoV-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther. 2020;108:775\u201390.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"580_CR7","doi-asserted-by":"publisher","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","volume":"64","author":"S Jeon","year":"2020","unstructured":"Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64(7):e00819\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"580_CR8","doi-asserted-by":"publisher","first-page":"CD013587","DOI":"10.1002\/14651858.CD013587","volume":"2","author":"B Singh","year":"2021","unstructured":"Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst Rev. 2021;2(2):CD013587. https:\/\/doi.org\/10.1002\/14651858.CD013587.","journal-title":"Cochrane Database Syst Rev"},{"key":"580_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijid.2020.11.191","volume":"103","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214\u20136.","journal-title":"Int J Infect Dis"},{"key":"580_CR10","doi-asserted-by":"publisher","first-page":"e0247163","DOI":"10.1371\/journal.pone.0247163","volume":"16","author":"P Behera","year":"2021","unstructured":"Behera P, Patro BK, Singh AK, Chandanshive PD, Ravikumar SR, Pradhan SK, et al. Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study. PLoS One. 2021;16:e0247163.","journal-title":"PLoS One"},{"key":"580_CR11","doi-asserted-by":"publisher","first-page":"100720","DOI":"10.1016\/j.eclinm.2020.100720","volume":"32","author":"C Chaccour","year":"2021","unstructured":"Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo P, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021;32:100720.","journal-title":"EClinicalMedicine"},{"key":"580_CR12","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ijid.2021.02.014","volume":"105","author":"R Lima-Morales","year":"2021","unstructured":"Lima-Morales R, M\u00e9ndez-Hern\u00e1ndez P, Flores YN, Osorno-Romero P, Cuecuecha-Rugerio E, Nava-Zamora A, et al. Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. Int J Infect Dis. 2021;105:598\u2013605.","journal-title":"Int J Infect Dis"},{"key":"580_CR13","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1097\/MJT.0000000000001377","volume":"28","author":"P Kory","year":"2021","unstructured":"Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of the emerging evidence demonstrating the efficacy of Ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther. 2021;28:e299\u2013318.","journal-title":"Am J Ther"},{"key":"580_CR14","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"L Caly","year":"2020","unstructured":"Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res. 2020;178:104787.","journal-title":"Antivir Res"},{"key":"580_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.bbrc.2020.10.042","volume":"538","author":"DA Jans","year":"2021","unstructured":"Jans DA, Wagstaff KM. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ? Biochem Biophys Res Commun. 2021;538:163\u201372.","journal-title":"Biochem Biophys Res Commun"},{"key":"580_CR16","doi-asserted-by":"crossref","unstructured":"Elalfy H, Besheer T, El-Mesery A, El-Gilany A-H, Abd Elazez MS, Alhawarey A, et al. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19. J Med Virol. 2021;93(5):3176\u201383.","DOI":"10.1002\/jmv.26880"},{"key":"580_CR17","first-page":"177","volume":"59","author":"J Remme","year":"1990","unstructured":"Remme J, De Sole G, Dadzie KY, Alley ES, Baker RH, Habbema JD, et al. Large scale ivermectin distribution and its epidemiological consequences. Acta Leiden. 1990;59:177\u201391.","journal-title":"Acta Leiden"},{"issue":"12","key":"580_CR18","first-page":"443","volume":"13","author":"A Mostafa","year":"2020","unstructured":"Mostafa A, Kandeil A, AMME Elshaier Y, Kutkat O, Moatasim Y, Rashad AA, et al. FDA-approved drugs with potent in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2. Pharm J. 2020;13(12):443.","journal-title":"Pharm J"},{"key":"580_CR19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","volume":"6","author":"J Xu","year":"2020","unstructured":"Xu J, Shi P-Y, Li H, Zhou J. Broad Spectrum antiviral agent Niclosamide and its therapeutic potential. ACS Infect Dis. 2020;6:909\u201315.","journal-title":"ACS Infect Dis"},{"key":"580_CR20","doi-asserted-by":"publisher","first-page":"19963","DOI":"10.1038\/s41598-020-77003-3","volume":"10","author":"P Kanjanasirirat","year":"2020","unstructured":"Kanjanasirirat P, Suksatu A, Manopwisedjaroen S, Munyoo B, Tuchinda P, Jearawuttanakul K, et al. High-content screening of Thai medicinal plants reveals Boesenbergia rotunda extract and its component Panduratin a as anti-SARS-CoV-2 agents. Sci Rep. 2020;10:19963.","journal-title":"Sci Rep"},{"key":"580_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed LJ, Muench H. A simple method of estimating fifty percent enpoint. Am J Epidemiol. 1938;27:493\u20137.","journal-title":"Am J Epidemiol"},{"key":"580_CR22","doi-asserted-by":"publisher","unstructured":"Ganguly D, Rottet S, Yee S, Hee W, Smith A, Khin N, Millar A, Fahrer A. SYBR green one-step qRT-PCR for the detection of SARS-CoV-2 RNA in saliva. bioRxiv.\u00a02020:05.29.109702. https:\/\/doi.org\/10.1101\/2020.05.29.109702.","DOI":"10.1101\/2020.05.29.109702"},{"key":"580_CR23","doi-asserted-by":"publisher","first-page":"e04050","DOI":"10.1016\/j.heliyon.2020.e04050","volume":"6","author":"N Niyomdecha","year":"2020","unstructured":"Niyomdecha N, Suptawiwat O, Boonarkart C, Jitobaom K, Auewarakul P. Inhibition of human immunodeficiency virus type 1 by niclosamide through mTORC1 inhibition. Heliyon. 2020;6:e04050.","journal-title":"Heliyon"},{"issue":"22","key":"580_CR24","first-page":"00008","volume":"S1672-0229","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteomics Bioinformatics. 2022;S1672-0229(22):00008\u20130.","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"6","key":"580_CR25","first-page":"285","volume":"3","author":"S Loewe","year":"1953","unstructured":"Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 1953;3(6):285\u201390 PMID: 13081480.","journal-title":"Arzneimittelforschung"},{"key":"580_CR26","doi-asserted-by":"publisher","first-page":"104878","DOI":"10.1016\/j.antiviral.2020.104878","volume":"181","author":"A Pizzorno","year":"2020","unstructured":"Pizzorno A, Padey B, Dubois J, Julien T, Traversier A, Duli\u00e8re V, et al. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antivir Res. 2020;181:104878.","journal-title":"Antivir Res"},{"key":"580_CR27","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1021\/jm070295s","volume":"50","author":"C-C Wen","year":"2007","unstructured":"Wen C-C, Kuo Y-H, Jan J-T, Liang P-H, Wang S-Y, Liu H-G, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem. 2007;50:4087\u201395.","journal-title":"J Med Chem"},{"key":"580_CR28","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1128\/AAC.48.7.2693-2696.2004","volume":"48","author":"C-J Wu","year":"2004","unstructured":"Wu C-J, Jan J-T, Chen C-M, Hsieh H-P, Hwang D-R, Liu H-W, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by Niclosamide. Antimicrob Agents Chemother. 2004;48:2693\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"580_CR29","doi-asserted-by":"publisher","first-page":"5770","DOI":"10.1038\/s41467-019-13659-4","volume":"10","author":"NC Gassen","year":"2019","unstructured":"Gassen NC, Niemeyer D, Muth D, Corman VM, Martinelli S, Gassen A, et al. SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-coronavirus infection. Nat Commun. 2019;10:5770.","journal-title":"Nat Commun"},{"key":"580_CR30","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nm.4184","volume":"22","author":"M Xu","year":"2016","unstructured":"Xu M, Lee EM, Wen Z, Cheng Y, Huang WK, Qian X, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med. 2016;22:1101\u20137.","journal-title":"Nat Med"},{"key":"580_CR31","doi-asserted-by":"publisher","first-page":"8670","DOI":"10.1021\/jm201264t","volume":"54","author":"AV Stachulski","year":"2011","unstructured":"Stachulski AV, Pidathala C, Row EC, Sharma R, Berry NG, Lawrenson AS, et al. Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication. J Med Chem. 2011;54:8670\u201380.","journal-title":"J Med Chem"},{"key":"580_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","volume":"1","author":"PB Madrid","year":"2015","unstructured":"Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, et al. Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis. 2015;1:317\u201326.","journal-title":"ACS Infect Dis"},{"key":"580_CR33","first-page":"e13503","volume":"74","author":"G Thomson","year":"2020","unstructured":"Thomson G. COVID-19: social distancing, ACE 2 receptors, protease inhibitors and beyond? Int J Clin Pract. 2020;74:e13503.","journal-title":"Int J Clin Pract"},{"key":"580_CR34","doi-asserted-by":"publisher","first-page":"e1002976","DOI":"10.1371\/journal.ppat.1002976","volume":"8","author":"A Jurgeit","year":"2012","unstructured":"Jurgeit A, McDowell R, Moese S, Meldrum E, Schwendener R, Greber UF. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog. 2012;8:e1002976.","journal-title":"PLoS Pathog"},{"key":"580_CR35","doi-asserted-by":"publisher","first-page":"e0198389","DOI":"10.1371\/journal.pone.0198389","volume":"13","author":"MT Schweizer","year":"2018","unstructured":"Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, et al. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS One. 2018;13:e0198389\u20139.","journal-title":"PLoS One"},{"key":"580_CR36","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0163-7258(82)90064-X","volume":"19","author":"P Andrews","year":"1982","unstructured":"Andrews P, Thyssen J, Lorke D. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19:245\u201395.","journal-title":"Pharmacol Ther"},{"key":"580_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2014.04.003","volume":"349","author":"Y Li","year":"2014","unstructured":"Li Y, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ. Multi-targeted therapy of cancer by niclosamide: a new application for an old drug. Cancer Lett. 2014;349:8\u201314.","journal-title":"Cancer Lett"},{"key":"580_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12885-018-4197-9","volume":"18","author":"S Burock","year":"2018","unstructured":"Burock S, Daum S, Keilholz U, Neumann K, Walther W, Stein U. Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial. BMC Cancer. 2018;18:297.","journal-title":"BMC Cancer"},{"key":"580_CR39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","volume":"3","author":"A Savarino","year":"2003","unstructured":"Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today\u2019s diseases? Lancet Infect Dis. 2003;3:722\u20137.","journal-title":"Lancet Infect Dis"},{"key":"580_CR40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","volume":"585","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, M\u00f6sbauer K, Hofmann-Winkler H, Kaul A, Kleine-Weber H, Kr\u00fcger N, et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature. 2020;585:588\u201390.","journal-title":"Nature"},{"key":"580_CR41","doi-asserted-by":"publisher","first-page":"104760","DOI":"10.1016\/j.antiviral.2020.104760","volume":"177","author":"SNY Yang","year":"2020","unstructured":"Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin \u03b1\/\u03b21 heterodimer. Antivir Res. 2020;177:104760.","journal-title":"Antivir Res"},{"key":"580_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","volume":"20","author":"NJ Barrows","year":"2016","unstructured":"Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, et al. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe. 2016;20:259\u201370.","journal-title":"Cell Host Microbe"},{"key":"580_CR43","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1042\/BJ20120150","volume":"443","author":"KM Wagstaff","year":"2012","unstructured":"Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443:851\u20136.","journal-title":"Biochem J"},{"key":"580_CR44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.antiviral.2013.06.002","volume":"99","author":"MY Tay","year":"2013","unstructured":"Tay MY, Fraser JE, Chan WK, Moreland NJ, Rathore AP, Wang C, et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antivir Res. 2013;99:301\u20136.","journal-title":"Antivir Res"},{"key":"580_CR45","doi-asserted-by":"publisher","first-page":"e0006934","DOI":"10.1371\/journal.pntd.0006934","volume":"12","author":"T-L Xu","year":"2018","unstructured":"Xu T-L, Han Y, Liu W, Pang X-Y, Zheng B, Zhang Y, et al. Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus. PLoS Negl Trop Dis. 2018;12:e0006934.","journal-title":"PLoS Negl Trop Dis"},{"key":"580_CR46","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/1087057110390360","volume":"16","author":"KM Wagstaff","year":"2011","unstructured":"Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA. An AlphaScreen\u00ae-based assay for high-throughput screening for specific inhibitors of nuclear import. J Biomol Screen. 2011;16:192\u2013200.","journal-title":"J Biomol Screen"},{"key":"580_CR47","doi-asserted-by":"publisher","first-page":"23138","DOI":"10.1038\/srep23138","volume":"6","author":"V G\u00f6tz","year":"2016","unstructured":"G\u00f6tz V, Magar L, Dornfeld D, Giese S, Pohlmann A, H\u00f6per D, et al. Influenza a viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci Rep. 2016;6:23138\u20138.","journal-title":"Sci Rep"},{"key":"580_CR48","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.21873\/invivo.12134","volume":"34","author":"S Lehrer","year":"2020","unstructured":"Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. In Vivo. 2020;34:3023\u20136.","journal-title":"In Vivo"},{"key":"580_CR49","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41429-021-00491-6","volume":"75","author":"AK Zaidi","year":"2022","unstructured":"Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of ivermectin against SARS-CoV-2\u2014an extensive review. J Antibiot. 2022;75:60\u201371.","journal-title":"J Antibiot"},{"key":"580_CR50","first-page":"CD015017","volume":"28","author":"MSM Popp","year":"2021","unstructured":"Popp MSM, Metzendorf MI, Gould S, Kranke P, Meybohm P, Skoetz N, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. 2021;28:CD015017.","journal-title":"Cochrane Database Syst Rev"},{"key":"580_CR51","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12879-021-06348-5","volume":"21","author":"J Vallejos","year":"2021","unstructured":"Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. BMC Infect Dis. 2021;21:635.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"580_CR52","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamainternmed.2022.0189","volume":"182","author":"SCL Lim","year":"2022","unstructured":"Lim SCL, Hor CP, Tay KH, Mat Jelani A, Tan WH, Ker HB, et al. Efficacy of Ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: the I-TECH randomized clinical trial. JAMA Intern Med. 2022;182(4):426\u201335.","journal-title":"JAMA Intern Med"},{"key":"580_CR53","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1097\/MJT.0000000000001402","volume":"28","author":"A Bryant","year":"2021","unstructured":"Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, et al. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021;28:e434\u201360.","journal-title":"Am J Ther"},{"key":"580_CR54","doi-asserted-by":"publisher","first-page":"e0006020","DOI":"10.1371\/journal.pntd.0006020","volume":"12","author":"J Mu\u00f1oz","year":"2018","unstructured":"Mu\u00f1oz J, Ballester MR, Antonijoan RM, Gich I, Rodr\u00edguez M, Colli E, et al. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLoS Negl Trop Dis. 2018;12:e0006020.","journal-title":"PLoS Negl Trop Dis"},{"key":"580_CR55","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s002280050131","volume":"50","author":"OZ Baraka","year":"1996","unstructured":"Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996;50:407\u201310.","journal-title":"Eur J Clin Pharmacol"},{"key":"580_CR56","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/cpt.1889","volume":"108","author":"VD Schmith","year":"2020","unstructured":"Schmith VD, Zhou J, Lohmer LRL. The approved dose of Ivermectin alone is not the ideal dose for the treatment of COVID-19. Clin Pharmacol Ther. 2020;108:762\u20135.","journal-title":"Clin Pharmacol Ther"},{"key":"580_CR57","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0304-4017(99)00175-2","volume":"87","author":"A Lifschitz","year":"2000","unstructured":"Lifschitz A, Virkel G, Sallovitz J, Sutra JF, Galtier P, Alvinerie M, et al. Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle. Vet Parasitol. 2000;87:327\u201338.","journal-title":"Vet Parasitol"},{"key":"580_CR58","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1021\/jf00101a015","volume":"38","author":"SHL Chiu","year":"1990","unstructured":"Chiu SHL, Green ML, Baylis FP, Eline D, Rosegay A, Meriwether H, et al. Absorption, tissue distribution, and excretion of tritium-labeled ivermectin in cattle, sheep, and rat. J Agric Food Chem. 1990;38:2072\u20138.","journal-title":"J Agric Food Chem"},{"key":"580_CR59","doi-asserted-by":"publisher","first-page":"e0008835","DOI":"10.1371\/journal.pntd.0008835","volume":"14","author":"K Kongmanas","year":"2020","unstructured":"Kongmanas K, Punyadee N, Wasuworawong K, Songjaeng A, Prommool T, Pewkliang Y, et al. Immortalized stem cell-derived hepatocyte-like cells: an alternative model for studying dengue pathogenesis and therapy. PLoS Negl Trop Dis. 2020;14:e0008835.","journal-title":"PLoS Negl Trop Dis"},{"key":"580_CR60","doi-asserted-by":"publisher","first-page":"e586","DOI":"10.1093\/cid\/ciaa1332","volume":"72","author":"Y Suputtamongkol","year":"2021","unstructured":"Suputtamongkol Y, Avirutnan P, Mairiang D, Angkasekwinai N, Niwattayakul K, Yamasmith E, et al. Ivermectin accelerates circulating nonstructural protein 1 (NS1) clearance in adult dengue patients: a combined phase 2\/3 randomized double-blinded placebo controlled trial. Clin Infect Dis. 2021;72:e586\u201393.","journal-title":"Clin Infect Dis"},{"key":"580_CR61","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.ymthe.2020.12.016","volume":"29","author":"T Bobrowski","year":"2021","unstructured":"Bobrowski T, Chen L, Eastman RT, Itkin Z, Shinn P, Chen CZ, et al. Synergistic and antagonistic drug combinations against SARS-CoV-2. Mol Ther. 2021;29:873\u201385.","journal-title":"Mol Ther"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-022-00580-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-022-00580-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-022-00580-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T09:12:48Z","timestamp":1655543568000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-022-00580-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,18]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1186\/s40360-022-00580-8","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,18]]},"assertion":[{"value":"5 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This work does not involve the use of human subjects and animals. All the procedures do not require IRB approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This work does not contain data from any individual person.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}